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Abstract
Rare disease represents one of the most significant issues facing the medical community and health care providers
worldwide, yet the majority of these disorders never emerge from their obscurity, drawing little attention from the
medical community or the pharmaceutical industry. The challenge therefore is how best to mobilize rare disease
stakeholders to enhance basic, translational and clinical research to advance understanding of pathogenesis and
accelerate therapy development. Here we describe a rare, fatal brain disorder known as Niemann-Pick type C (NPC)
and an innovative research collaborative known as Support of Accelerated Research for NPC (SOAR-NPC) which
illustrates one pathway through which knowledge of a rare disease and its possible treatments are being
successfully advanced. Use of the “SOAR” mechanism, we believe, offers a blueprint for similar advancement for
many other rare disorders.
Keywords: Cyclodextrin, Collaborative science, Drug pipeline, Lysosomal disease, Miglustat, Niemann-Pick C, Patient
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Background
Although defined somewhat differently country to coun-
try, it is broadly estimated that there are approximately
7,000 rare diseases. In the U.S., a rare disease is defined
as affecting fewer than 200,000 individuals, and rare dis-
eases collectively as many as 30–35 million people. In
Europe estimates are similar, with as many as 350 mil-
lion individuals affected worldwide. Yet such large num-
bers stand in sharp contrast to the reality of most rare
diseases for which there are only a handful of diagnosed
individuals in an entire country. While the majority of
rare diseases are genetic and the genes and mutations
known for a rapidly increasing proportion, knowledge of
disease often ends there, with only partial understanding
of the role of the defective protein in cells and even less
being known about disease pathogenesis. Nonetheless,
understanding the function of rare disease-linked genes
and their proteins can provide new insights into how
cells function, which in turn may lead to insights into,
and therapies for, both rare and common diseases.
Not surprisingly, the road from rare disease discovery
to implementation of successful therapies is inevitably
long and must take into consideration many factors.
These range from disease recognition and discovery of
the cause of the disease and its pathogenesis, to natural
history studies to provide a clearer understanding of
how a particular rare disorder affects different individ-
uals, to establishment of clinics to facilitate patient care.
For some, discovery of the disease may have been more
than a century ago, as for diseases like Niemann-Pick,
whereas for others a matter of only a few years or less.
While much progress has been made in defining the
molecular basis of many genetic diseases, large gaps re-
main in our understanding of the complex chain of
events between the underlying genetic defect and the
phenotypic abnormalities at various levels from cells, tis-
sues, and organs, to the whole organism. Since studies
necessary for unraveling these pathogenic mechanisms
often cannot be done in humans or with human tissues,
* Correspondence: Steve.Walkley@einstein.yu.edu
1Dominick P. Purpura Department of Neuroscience, Rose F. Kennedy
Intellectual and Developmental Disabilities Research Center, Albert Einstein
College of Medicine, 1410 Pelham Parkway South, Bronx, NY 10461, USA
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Walkley et al. Orphanet Journal of Rare Diseases  (2016) 11:161 
DOI 10.1186/s13023-016-0540-x
animals with the same genetic disorders are a critical re-
source for knowledge advancement. Appropriate animal
models also provide a means to test new therapies, with
mice, cats, dogs, and non-human primates increasingly
recognized as important intermediate models to assess
these strategies.
While a key goal for rare disease advancement is the de-
velopment of clinical trials to test potential therapies, lim-
ited availability of affected patients often imposes
significant constraints that require international cooper-
ation to overcome. Fundamental to progress is the develop-
ment of natural history studies, the purpose of which is to
characterize the range of phenotypic heterogeneity and
variability of disease progression. Information is obtained
about frequency of signs and symptoms, age of onset, and
disease progression. This information can be used to iden-
tify potential outcome measures for later therapeutic trials.
Once the variability and rate of progression of a specific
disease-related sign or symptom is known, the information
can be used to adequately power a controlled clinical trial.
From a natural history study, one also quickly learns infor-
mation regarding the practicality and potential difficulties
associated with obtaining data on a specific outcome meas-
ure. A second key aspect of natural history studies is that
they provide a mechanism to collect patient biomaterials,
including serum/plasma, urine, cerebrospinal fluid (CSF),
DNA, and patient cells. These biomaterials provide a re-
source that can be used by scientists in studies focused on
understanding the pathological processes underlying the
disorder, as well as used to identify biomarkers to facilitate
diagnosis or as tools to support the development of clinical
trials. Such biomarkers may be any identified biochemical,
genomic or proteomic feature, or even an imaging marker
that serves as a measurable indicator of the disease state.
Once validated in clinical trials against clinical outcome
measures, these biomarkers have the potential to serve as
surrogate outcome measures. Ultimately if validated as a
surrogate, since they may respond quicker than clinical
signs or symptoms, biomarkers could accelerate drug devel-
opment by facilitating shorter and smaller clinical trials.
Natural history studies are complemented by patient regis-
tries, which serve as a resource to identify patients who
may be interested in participating in a clinical trial as well
as to provide information on disease phenotype and pro-
gression. They have the potential advantage of being able to
ascertain information from individuals who are not able to
travel to a study site in order to participate in a natural his-
tory study.
Development of natural history studies and registries,
biomarker discovery, and expanded understanding of
disease pathogenesis through availability of animal
models (that can also be used for preclinical testing of
specific treatments), effectively set the stage for clinical
trials. Formal clinical trials in which data are collected in
a rigorous and standardized manner are essential for ap-
proval of a drug by regulatory agencies. Prior to approval
of a drug the Food and Drug Administration (FDA) re-
quires that efficacy be shown “through adequate and
well-controlled clinical studies” (21CFR314.126). Al-
though well-documented case reports and case-series
may provide information related to safety and insight
into potential outcome measures for a subsequent well-
controlled trial, they are not controlled studies and
therefore would not be adequate for regulatory approval.
While the above cycle of progress for a rare disease
may appear fully exploitable through an academic med-
ical center or network of such centers, in reality, the im-
portance of patient advocacy as catalyst and supporter of
these studies cannot be overstated. Disease advocates
participate and have direct input in the process by bring-
ing scientists together, organizing within the patient
community, holding meetings/conferences with scien-
tists and patient advocates, and funding early-stage,
high-risk research through grants, both directly to re-
searchers and by leveraging other funding. It is also crit-
ical to foster and support public-private partnerships by
developing relationships with government agencies and
industry. Patient liaisons that learn and understand the
drug development and FDA regulatory process empower
advocates to be more fully engaged and to interact with
scientists and regulators. In order to build a collabor-
ation and strong partnership, it is important to establish
a relationship of trust and engagement between patient
advocates and the scientists/clinicians to foster product-
ive ways of working together. Key elements of the rela-
tionship are communication and mutual respect for each
other’s roles, including the establishment of defined
boundaries and organizational structure so that the rela-
tionship remains collaborative and productive. Scientists
know science and are pragmatic; parents are pragmatic
in a different way, focused on saving their children’s lives
and bringing other perspectives and strategies to solving
problems and implementing ideas that benefit the pa-
tient community. Several years ago a group of scientists,
clinicians and parents came together in an attempt to
overcome the obstacles inherent in developing an effect-
ive therapy for the rare brain disease known as
Niemann-Pick type C, and in the process created an in-
novative research collaborative known as Support of
Accelerated Research for Niemann-Pick C disease
(SOAR-NPC) (Fig. 1). That experience is described here
and we propose that it can serve as a basis for advancing
therapies for other rare disorders.
Niemann-pick type C disease, a model example
NPC disease is a rare, progressive, neurodegenerative
disorder characterized by storage of unesterified choles-
terol in the late endosomal/lysosomal system. Two genes
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(NPC1 and NPC2) have been linked to NPC disease in
humans, with 95% of cases associated with mutations in
NPC1. NPC1 is a multi-spanning transmembrane pro-
tein and NPC2 is a soluble cholesterol-binding protein,
both of which reside in late endosomes/lysosomes [1].
The incidence of classical NPC1 disease has been esti-
mated to be 1/89,000-104,000 [1], whereas a late-onset
variant of NPC1 has a predicted incidence of 1/39,000
based on analysis of NPC1 carrier frequency from large-
scale exome sequencing [2]. Affected individuals typic-
ally present with visceral involvement as neonates,
progressing in early childhood with ataxia and impair-
ment of motor and intellectual function, and usually die
in adolescence. Late-onset NPC1 disease increasingly is
being recognized in young adults with psychoses and
cognitive impairment, with a disease prevalence of ~2%
among this population [3].
The discovery of NPC1 disease biomarkers has trans-
formed the diagnosis of NPC1 disease and accelerated
drug development efforts. Until recently, the first-line
diagnostic test for NPC disease was filipin staining of
cultured primary skin fibroblasts for cholesterol. The
discovery in one of the SOAR-NPC labs (Ory) that oxy-
sterols are sensitive and specific disease markers [4] has
led to development of a clinical assay that has been im-
plemented in more than 30 laboratories worldwide and
is replacing the filipin test as the diagnostic standard [5].
More recently, metabolomic profiling led to identifica-
tion of unusual bile acid species that are specifically ele-
vated in the plasma of NPC1 disease patients [6]. A
high-throughput, mass spectrometry-based method was
developed and validated to measure the bile acid bio-
markers in dried blood spots with their quantification
providing the basis for a newborn screen for NPC dis-
ease. This screen is now ready for piloting in newborn
screening programs.
Establishment of an NPC disease natural history study
at NIH in 2006 (NCT00344331) provided the means to
characterize the clinical phenotype and phenotypic het-
erogeneity of NPC1 disease across a large number of
Fig. 1 SOAR-NPC organizational chart. At the center of SOAR-NPC is the Collaborative, the scientific core which maintains vital relationships and
open communication with other key groups (arrows). Ongoing interactions amongst groups facilitate SOAR-NPC’s ability to rapidly respond to a
dynamic research environment. See text for additional details
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patients in both a cross-sectional and longitudinal manner
(Porter). The longitudinal nature of this study allowed for
disease progression to be characterized and a Neurological
Severity Score to be developed [7]. This scoring system
assessed disease progression in nine major and eight
minor sign/symptom domains that are clinically relevant
to NPC disease progression. The scale was found to be
useful both retrospectively and prospectively to
characterize disease status and progression. The NPC1
disease natural history study also provided an opportunity
to establish a biorepository of blood, CSF, and fibroblasts
from well characterized patients. These samples subse-
quently proved invaluable in the identification and
characterization of pharmacodynamic biomarkers [8] and
biomarkers of neuronal damage such as tau [9], FABP3
[10] and calbindin D [11]. These biomaterials were also
essential for development of the assay for newborn screen-
ing for NPC disease mentioned earlier [6].
In addition to defining the gene defect in NPC1 disease,
developing disease-specific biomarkers and establishing a
natural history study, the NPC research community has
also identified disease models in multiple species. These in-
clude simple non-mammalian systems – S. cerevisiae, C.
elegans, D. melanogaster, and Danio rerio-as well as M.
musculus and F. catus mammalian models. Several mouse
models are available including both spontaneous mutations
(e.g. BALB/cNctr-Npc1m1N/J, C57BLKS/J-Npc1spm/J) and
targeted or chemically induced mutations (e.g. B6.129-
Npc1tm1.1Dso/J, p.I1061T, c.3182 T > C; C57BL/6 J-
Npc1nmf164/J, p.D1005G, c.3163A >G; and an NPC2
hypomorphic allele). The most widely used mouse model
is the Npc1m1N, a null model initially characterized at the
NIH [12–14]. These mice exhibit weight loss, severe ataxia,
and intracellular accumulation of cholesterol and other
lipids, all prominent clinical and pathological manifesta-
tions seen in NPC1 patients. A humanized hypomorphic
Npc1tm1.1Dso mouse model was also recently developed in
one of the SOAR-NPC labs (Ory). Here, the p.I1061T
(c.3182 T >C) mutation, the most prevalent human disease
allele, was inserted into the Npc1 locus [15]. Npc1I1061T/
I1061T “knock-in” mice show an increased mean survival
time as compared with Npc1m1N/m1N mice, consistent with
partial function of the mutant protein. Onset of neuro-
logical signs is delayed 3 weeks, and the progression of
signs and weight loss are less precipitous.
The discovery of a large animal model of NPC1 disease
occurring spontaneously in cats [16] has proven to be a
critical resource for advancing therapy. Here, the disorder
results from a single missense mutation in NPC1
(p.C955S, c.2864G > C) that most closely models the clin-
ical disease features of juvenile-onset NPC1 disease
patients (the most common form of NPC1 disease) [17].
The cat model displays ectopic dendritogenesis, a key
neuropathological feature of many lysosomal disorders in
humans and is a finding that occurs only minimally in
murine models of these diseases [18]. Furthermore, the
NPC1 cats exhibit a massive degree of neuroaxonal dys-
trophy, thereby recapitulating another critical aspect of
the cellular pathology of NPC1 disease. A breeding colony
of NPC1 cats has been established at the National Referral
Center for Animal Models of Human Genetic Disease of
the School of Veterinary Medicine of the University of
Pennsylvania by one of the SOAR-NPC scientists (Vite).
The size of the feline model allows for the ability to both
repeatedly administer experimental therapies intraven-
ously or intrathecally and to repeatedly sample blood,
urine, and CSF. This model has also allowed for validation
of biochemical markers of disease severity and therapeutic
effects that are specific to central nervous system (CNS)
disease. Finally, its large size also allows for the develop-
ment of metrics of disease progression using equipment
identical to those used in people, e.g., magnetic resonance
imaging (MRI) and electrodiagnostic testing. The cat
model has been extensively used to evaluate the efficacy of
experimental therapies of NPC disease [19–21].
The mammalian models of NPC1 disease have been
particularly valuable in allowing for studies of NPC disease
pathogenesis. Through such analysis it is now known that
cholesterol, glycosphingolipids (GSLs), particularly GM2
and GM3 gangliosides and lactosylceramide, are abnor-
mally sequestered in brain cells in NPC disease [22, 23].
Endosomal/lysosomal storage of gangliosides without
clear evidence of deficiency of ganglioside catabolic en-
zymes in the NPC1 mouse and cat models led Walkley
and colleagues to speculate that this might be the result of
increased GSL synthesis [24]. Subsequent studies using
the GSL synthesis inhibitor, N-butyl-deoxynojirimycin or
miglustat, in the NPC1 models were the first to demon-
strate delay in onset of neurological disease and increased
longevity for this disease [25], a finding subsequently ex-
tended with additional studies in the feline model [19].
Today, miglustat is an approved therapy for NPC1 disease
in 45 countries, though not in the U.S.
Most of the support for the above studies on NPC dis-
ease was derived from work funded through the “classic”
model of peer-reviewed investigator-initiated projects.
These were largely funded through the NIH using the
widely recognized “R01” and “R21” mechanisms and by
private foundations such as the Ara Parseghian Medical
Research Foundation (APMRF) and the National
Niemann-Pick Disease Foundation (NNPDF) following
review by their scientific advisory boards. Importantly,
funding by these private foundations often provided crit-
ical support for high risk, high impact projects that
would not have been supported via traditional funding
routes, such as the NIH. Grants supported by the
APMRF, for example, led directly to identification of the
NPC1 gene, to improved understanding of the function
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of the NPC1 and NPC2 proteins and to the discovery of
miglustat’s ameliorative effects on NPC disease. The
APMRF also provided critical support for the initiation
of the NPC natural history study described earlier. Yet
despite these and other important advances for NPC dis-
ease, there was also a growing realization among some
parents that a critical element for progress was missing.
This was the pre-clinical and clinical expertise similar to
that which pharmaceutical companies would have for ef-
fectively and fully developing therapies for this fatal neu-
rodegenerative disease. It was in this mixed atmosphere
of hope and realization that a complementary approach
to research support was born, one focused specifically
on development of NPC1 disease therapies.
Emergence of SOAR-NPC
The idea of the research collaborative known as SOAR-
NPC emerged when three researchers and a parent trav-
eled to Brazil in 2007 to visit the family of a young adult
patient who had the disease. The patient’s father was a
potential funder of NPC disease research and the visitors
wanted to prepare something more than a simple listing
of potential therapeutic strategies. Inspired by a collab-
orative research model that had been developed by the
Myelin Repair Foundation [26], SOAR-NPC was con-
ceived to incentivize and maximize scientific collabor-
ation. Its ambitious objective, stated at the outset, was to
develop, within 3–5 years, an FDA sanctioned clinical
trial with emphasis on development of a combination
therapy-or “cocktail” – that would prevent or signifi-
cantly delay the onset and progression of clinical neuro-
logical disease in individuals affected by this disorder.
Toward this end, the initial family foundations in sup-
port of SOAR-NPC (Dana’s Angels Research Trust and
the Hide and Seek Foundation for Lysosomal Disease
Research) established a funding stream for NPC disease
research in 2008 prior to its first multi-party
organizational meeting at Stanford University.
In creating the SOAR-NPC Collaborative (Fig. 1), the re-
searchers and families early on embraced the concept of a
small network of highly interactive/collaborative scientists.
Such individuals, it was decided, need not be at the same
institution or even in the same country; rather, it was crit-
ical to have a detailed knowledge and involvement with
NPC disease, and equally important, a strong willingness
by each scientist to be truly collaborative, planning experi-
ments and sharing data collection and analysis in real-
time. It was decided that scientists entering the SOAR-
NPC Collaborative must be willing to share unpublished
data to aid in rapid and efficient progress. Hosting confer-
ence calls every other week was viewed as an essential
element in coordinating activities. The number of scien-
tists was also thought to be critical. Too many, and the
close coordination between labs might be lost, yet too few
and a deficiency in critical complementary skills might
weaken research progress. Since the establishment of
SOAR-NPC the number of scientists has ranged from 3 to
4, with 2 of the scientists (Ory and Walkley) being part of
the collaborative since its inception. While the SOAR-
NPC scientists elected their own group leader (Ory), it
was also quickly realized that the group would need a sci-
entific coordinator to act as project manager as well as li-
aison with the SOAR-NPC parent groups. This role was
filled by different individuals over the years (including
Ottinger) and continues to evolve with the changing needs
of SOAR-NPC. Currently, this individual (Davidson)
schedules the biweekly conference calls and biannual face-
to-face meetings of the scientists and parents, as well as
follows up on research questions arising in the scientific
exchanges during the teleconferences or in discussions
with parents. As unpublished data is constantly under dis-
cussion, agreement to maintain confidentiality by all par-
ties involved has proved vital to success. Given the
importance of the goal to accelerate therapy for NPC1 dis-
ease, the collaborative established connections early on to
the NPC1 disease natural history study being carried out
at the National Institutes of Health (Porter). With the dis-
covery of 2-hydroxypropyl-β-cyclodextrin’s (HPβCD) re-
markable efficacy in animal models, this connection
proved essential for rapid acceleration toward a clinical
trial through links with NIH’s Therapeutics for Rare and
Neglected Diseases (TRND) Program in the new National
Center for Advancement of Translational Science
(NCATS), as described below. Critical to the operation of
SOAR-NPC has been its ability to identify and fund inves-
tigators outside the SOAR-NPC Collaborative who are
pursuing projects directed at therapy for NPC1 disease.
These adjunct projects, coordinated by the SOAR-NPC
research manager, have varied widely from those focused
on proteostatic and gene therapies, to preventing ototox-
icity following administration of cyclodextrin, to develop-
ing improved HPβCD formulations that cross the blood–
brain barrier. Such pilot projects typically have lasted a
year, or more, with funded scientists joining biweekly calls
with the SOAR-NPC scientists as data was ready for ana-
lysis and discussion (Fig. 1).
The collaborative character of SOAR-NPC is not lim-
ited to its scientific members as parents/guardians also
play a key role in a number of ways. The SOAR-NPC
families presently represent six individual foundations,
each of which pursues their own avenue(s) to raise
money to support NPC disease research. Resources are
then pooled in order to partially fund not only the
SOAR-NPC scientists, but also the smaller adjunct pro-
jects mentioned above that align with SOAR-NPC goals.
Biannual face-to-face meetings (Fig. 2) between SOAR-
NPC families and its scientists serve to not only share
progress of studies, but importantly, to reach consensus
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on what avenues are worth pursuing in future research
efforts, including those small pilot projects outside of
main SOAR-NPC laboratories. Whenever necessary as
part of such decisions on current and future research di-
rections, the SOAR-NPC Collaborative seeks advice
from its Research Advisory Committee (RAC). This
group, which was used most often in the early years of
SOAR-NPC, represents a small group of senior investi-
gators in the lysosomal disease and drug development
fields (Fig. 1). Overall, the biannual meetings of the Col-
laborative not only allow progress and plans to be
reviewed, but also provide an opportunity for the SOAR-
NPC families to understand the scientific merit of
proposed projects, permitting them to make informed
decisions on how pooled resources are utilized.
Beyond raising significant funds to support NPC1 dis-
ease research, parents are also involved in developing in-
tellectual property agreements as well as fostering new
relationships with researchers and the pharmaceutical
industry, in representing the NPC1 disease community
with government agencies, and in facilitating more regu-
lar and effective communication among the various
stakeholders. Perhaps most importantly, parents bring a
practical sense of urgency to the therapy-development
project. Just as they learn the realities and practicalities
of scientific research, parents bring their skill sets and
personal experiences to the SOAR-NPC enterprise in a
way that has tangibly accelerated the development of
therapeutic strategies.
The other major stakeholder in SOAR-NPC has been
the NIH, which has a long history as a partner in the
basic research and development of therapeutics for
NPC1 disease and as a facilitator of interactions between
the scientific and the NPC1 disease parent and patient
communities. Scientists at NIH first identified the cellular
defect in 1985 [27] followed years later by the cloning of
the NPC1 gene in 1997 [28] and subsequently imple-
mented the first clinical trial to test cholesterol-lowering
drugs. Shortly after SOAR-NPC was established in 2007,
its scientists met with researchers at the NIH Chemical
Genomics Center (NCGC), including its then scientific
director, Dr. Christopher P. Austin, in order to discuss
screening of patients’ cells, provided by participants en-
rolled in the on-going NPC disease natural history study
at NIH, with a collection of FDA-approved drugs. The
goal was to look for molecules that could reverse choles-
terol storage in cells, and as a result be “repurposed” as a
therapy for NPC1 disease, potentially shaving years off the
drug development timeline. In 2008, the NCGC received a
grant from the APMRF to support this high-throughput
screening effort. The collaboration with SOAR-NPC in-
vestigators involved testing the best lead compounds iden-
tified from the screening effort for in vivo efficacy in the
NPC disease animal models. The initial lead compound
identified from this screen and subsequently tested in the
NPC1 (BALB/cNctr-Npc1m1N/J) mouse model was a com-
ponent of Vitamin E [29], but the compound failed to
show efficacy in the mouse. Nonetheless, the close work-
ing relationship established between the NCGC and
SOAR-NPC scientists on this project laid the foundation
for cooperative development of a new lead compound that
was just emerging from several laboratories working on
NPC1 disease.
The discovery of cyclodextrin as therapy for NPC disease
By the early 2000s, an improved understanding of NPC1
disease allowed scientists to focus more efforts on ra-
tional therapeutic approaches, such as targeting down-
stream effects, reducing accumulating metabolites, and
as applicable, enhancing existing protein function. Pro-
jects focused on therapeutic intervention became more
commonplace. Around the same time the idea of SOAR-
NPC was taking shape, exciting new data from two inde-
pendent laboratories, John Dietschy, a scientist at
University of Texas Southwestern and Steven Walkley (a
SOAR-NPC scientist) was being shared at the 2007
APMRF annual meeting. Here, both investigators re-
ported the unexpected and surprising realization that
HPβCD, the vehicle or “excipient” used to solubilize a
putative therapeutic compound (allopregnanolone) [30],
provided far greater benefit in the NPC1 mouse model
than allopregnanolone itself, or indeed any compound
investigated thus far, including miglustat. Though an
earlier study investigated HPβCD for treatment of NPC1
disease, use of a much lower dose failed to elicit the sig-
nificant responses subsequently reported by the Dietschy
and Walkley labs [31–34]. Importantly, the studies from
these two groups revealed that treated mice not only
Fig. 2 SOAR-NPC Collaborative meeting. A face-to-face meeting of
SOAR-NPC members as occurred at the Rose F. Kennedy Center at the
Albert Einstein College of Medicine on February 26, 2014. Pictured are
(left to right), Daniel S. Ory, Cristin D. Davidson, Charles H. Vite, Steven U.
Walkley, Philip D. Marella and Sean Recke (not shown: Jonathan Jacoby).
Individuals shown have consented to having their pictures published
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exhibited delayed onset of clinical disease, but also
showed dramatically less storage of cholesterol and
sphingolipids and lived nearly twice their normal life-
span. Subsequent studies in a second SOAR-NPC lab
(Vite) treating the feline NPC1 model with HPβCD fur-
ther advanced the notion of this compound’s ability to
significantly impact the disease process. Indeed, direct
administration of HPβCD into the cerebellomedullary
cistern of presymptomatic cats with NPC disease pre-
vented the onset of cerebellar dysfunction for greater
than a year, and resulted in Purkinje cell survival and
near normal concentrations of brain cholesterol and
sphingolipids [21]. At the same time, an adverse effect
identified was an increase in hearing threshold. To-
gether, these studies in the feline model provided critical
data on efficacy and relative safety of direct CNS admin-
istration of the drug that have proven important in ad-
vancing the subsequent clinical trials. These substantial
preclinical studies, combined with HPβCD's overall
safety profile and many years of experience as an ex-
cipient in FDA-approved drugs, were largely respon-
sible for promoting this compound as SOAR-NPC’s
lead candidate for advancement to clinical trial. Dur-
ing the latter period of preclinical research, several
NPC1 disease families received approval from the
FDA for individual expanded access Investigational
New Drug (iIND) applications and their children
began receiving HPβCD intravenously. While acknow-
ledging the potential contribution of iINDs and first-
in-human treatment with the drug for contributing
information related to the safety of HPβCD, numer-
ous investigators involved in HPβCD preclinical work
and patient advocates realized the critical importance
of carrying out a scientifically rigorous clinical trial to
unambiguously establish safety and potential efficacy
of this compound, so that it could eventually gain
FDA approval. Accordingly, this effort became the
common goal amongst all involved in the push to-
wards establishing HPβCD as a bona fide therapy for
NPC1 disease.
In 2010, the NIH established the aforementioned
program known as TRND which subsequently became
an integral component of NCATS and incorporated
the NCGC scientists with whom SOAR-NPC had pre-
viously collaborated. TRND was specifically designed
to stimulate drug discovery and development for rare
and neglected diseases through a collaborative model
between the NIH, academic scientists, nonprofit orga-
nizations, and pharmaceutical and biotechnology com-
panies. That same year, the National Institute for
Neurological Disorders and Stroke (NINDS) spon-
sored the meeting, “Promising Therapies for NPC,”
organized by Drs. Steven Walkley and Danilo Tagle,
to bring together NPC1 disease researchers and
disease advocacy groups at NIH to discuss the
current state of knowledge and possible therapeutic
developments, focusing in part on the growing aware-
ness of the promise of HPβCD for treating NPC.
SOAR-NPC quickly recognized the potential for the
TRND program to provide critical support for develop-
ment of this compound as a therapeutic drug. In collabor-
ation with Dr. Forbes Porter at the NIH, SOAR-NPC
scientists (Ory and Walkley) developed a research pro-
posal that provided a roadmap for rapid translation of pre-
clinical studies of HPβCD to a Phase 1/2a trial at the NIH
Clinical Center. The proposal was accepted and in early
2011 development of HPβCD for the treatment of NPC1
was selected as one of TRND’s initial projects [35].
This effort required the establishment of a large col-
laborative team with a wide range of expertise in all
areas of drug development, including chemistry and
manufacturing, formulation, pharmacology, pharmaco-
kinetics, toxicology, and regulatory affairs, to advance
the molecule from basic discovery to clinical testing.
SOAR-NPC researchers (Ory, Vite and Walkley) became
key members in establishment of the TRND-NPC team
(Fig. 3), adding critical expertise in NPC1 disease animal
models and biomarker discovery and assay development.
In addition, a SOAR-NPC collaborator and leader of the
NPC1 disease Natural History study at the NIH Clinical
Center (Porter) provided clinical expertise in human
NPC1 disease and patient care. Importantly, the TRND-
NPC project manager (Ottinger) also provided project
management for SOAR-NPC, serving as a liaison that
helped to align the goals and interests of the parents
with the researchers and their plan for developing a
therapy for NPC1 disease. This centralized project man-
agement support and point of contact was found to be
key to driving the project forward to meet milestones
and the end goal, a Phase 1/2a clinical trial. It also en-
sured that the necessary resources were available,
tracked the TRND-NPC team activities and studies,
monitored overall project costs and fostered a cohesive
team environment. This coordinated team effort facili-
tated completion of all the needed pre-clinical studies,
leading to the successful initiation of the Phase 1/2a trial
of a defined HPβCD preparation at the NIH Clinical
Center in early 2013 [35, 36]. After years of effort in
supporting NPC1 disease research and the close partner-
ships forged between advocacy groups and the research
community, including the SOAR-NPC model, the NPC1
community had a drug candidate entering clinical stud-
ies. The extensive preclinical data package and early
clinical data from the Phase 1/2a study, coupled with
successful designation of HPβCD as an Orphan Drug in
the U.S. and EU, sufficiently de-risked the HPβCD pro-
gram such that TRND-NPC was able to able to attract
an industry partner. Vtesse, Inc., a pharmaceutical
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company, was founded to develop a specific HPβCD
preparation (VTS-270) for treatment of NPC1 disease,
and the Phase 2b/3 international, multi-site trial was
launched in September 2015. Vtesse’s VTS-270 re-
cently received the FDA’s Breakthrough Therapy Des-
ignation, which could accelerate approval to provide
the first effective treatment for slowing progress or
stabilizing the devastating impacts of NPC in chil-
dren and adolescents. The clinical trial has entered
Phase 3 and once again the NPC community, includ-
ing SOAR-NPC families and scientists, is mobilizing
its efforts with a parent/patient clinical trial recruit-
ment campaign called “51 and Done!” which ac-
knowledges the number of patients to be recruited
for the trial.
SOAR-NPC – An evolving strategy
At its inception, SOAR-NPC’s primary goal was to
initiate a clinical trial for NPC disease within a 3–5
year timeframe. Remarkably, this goal was accom-
plished in 2013, just under 5 years after the initiation
of funding for the SOAR-NPC scientists. This success
did not diminish the enthusiasm or desire to continue
pursuit of different therapeutic compounds. Although
VTS-270 holds substantial promise for treating NPC
disease, SOAR-NPC acknowledges VTS-270’s limita-
tions and the necessity of finding additive, and even
more optimal and tractable therapies. Early on, the
members of SOAR-NPC decided a drug pipeline was
essential to the success of efficient compound evalu-
ation. This drug pipeline prioritizes compounds of
interest while maintaining flexibility. When the pipe-
line was first conceived in 2007, 12 compounds of
interest were selected for evaluation. To date more
than 30 potential drugs have been processed through
this pipeline. While VTS-270 continues to receive
scientists’ attention, greater emphasis has recently
been placed on cutting-edge technologies such as
gene therapy and modulators of the proteostatic net-
work. Potential therapies failing to show improve-
ments in in vivo studies are accordingly removed
from the pipeline queue, thus allowing evolution and
incorporation of new compounds brought to light
through diligent awareness of new scientific literature
by the SOAR-NPC scientists and by parents in the
NPC1 disease community. As the list of compounds
grows, so too does the number of researchers brought
in to explore these different avenues. For example, a
workshop jointly funded by SOAR-NPC and the
APMRF on the topic of proteostatic modulation in
NPC disease brought an additional five researchers
into the fold as affiliate labs of SOAR-NPC. Efforts
such as this workshop not only foster the growth of
the NPC research community, but, equally as import-
ant, also increase its intellectual capacity and breadth.
Conclusions
Today’s scientific environment is slowly transitioning
from an atmosphere of scientists wary of sharing data
before publication to one with a much greater appre-
ciation for the power of collaboration. New relation-
ships between academia, industry, government, and
patient advocacy groups have allowed rapid progress
and brought patient welfare to the forefront. Rare dis-
eases, though often comprised of very small patient
groups, are finding their way to the leading edge of
research, sometimes for the simple reason that scien-
tists find the missing gene and defective protein as a
key to understanding some aspect of cell biology they
are pursuing. Not only are scientists beginning to
appreciate the applicability of knowledge gleaned from
rare diseases to more common maladies, but the
Fig. 3 TRND-NPC team members. First Row (Left to Right): Ilona Scott (Janssen Research & Development, LLC, Johnson & Johnson [J&J]), Patrick
Frenchick (RRD International, Inc. [RRD]), Sandra L. Morseth (RRD), Kimberly Lilly (RRD), Mark L. Kao (J&J), Nicole Y. Farhat (NIH/NICHD), Elizabeth A.
Ottinger (NIH/TRND), Nuria Carrillo (NIH/TRND), Xin Xu (NIH/TRND); Second Row (Left to Right): Steven U. Walkley (Albert Einstein College of Medicine),
Charles H. Vite (University of Pennsylvania), Charles Finn (RRD), Joy K. Vander Wal (RRD), Steven A. Silber (J&J), John C. McKew (NIH/TRND), Forbes D.
Porter (NIH/NICHD), Daniel S. Ory (Washington University School of Medicine), Christopher P. Austin (NIH/TRND), John Heiss (NIH/NINDS), Wei Zheng
(NIH/TRND); Missing Team Members: Juan J. Marugan (NIH/TRND), William J. Pavan (NIH/NHGRI), James Cradock (NIH/TRND) and Pramod Terse (NIH/
TRND) Individuals shown have consented to having their pictures published
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avenues and compounds being employed to treat
these often lethal conditions are also pushing the
therapeutic envelope. We have highlighted NPC1 dis-
ease and SOAR-NPC as an example of a successful
pathway for increasing knowledge of a rare disease
while efficiently advancing potential therapeutics to
clinical trial. Certainly SOAR-NPC is not unique as
an organization designed to advance rare disease re-
search and therapy for lysosomal diseases, e.g., see Jo-
nah’s Just Begun http://jonahsjustbegun.org/aboutus/;
The ML4 Foundation, http://ml4.org/; Team Sanfi-
lippo, http://teamsanfilippo.org/; Beyond Batten Dis-
ease http://beyondbatten.org/, the National Tay-Sachs
and Allied Diseases Foundation, http://www.tay-sach-
s.org/and others. Yet, SOAR-NPC appears unique in
its internal organization, which has been honed
through incorporation of a number of key features
(Table 1) to maximize its likelihood for success: selec-
tion of scientists willing to openly share data; incorp-
oration of family foundations able to provide critical
financial resources and who appreciate that the se-
lected scientists both acknowledge the importance of
and actively strive for therapy advancement; mainten-
ance of flexibility from key players permitting adapta-
tion to a rapidly changing environment, and
welcoming the expertise of outside scientists, even if
only for selected projects or a limited time; and most
importantly, creation of a cohesive group of people
with a shared vision to increase knowledge while sim-
ultaneously advancing therapeutics. Though there is
no single correct formula for achieving success, we
hope this blueprint using the “SOAR-NPC” model
may help others in the rare disease community in-
crease their knowledge and ultimately, improve the
well-being of the nearly 350 million individuals world-
wide who are united by the common designation of
having a “rare” disease.
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time; openness to new ideas; ability to maintain confidentiality
when needed within the SOAR.
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appropriate to the SOAR’s objectives. Selection should be based on
their research backgrounds, their genuine willingness to work
collaboratively and openly share unpublished data and their
familiarity and willingness to establish relationships with patients
and families.
3. Clearly identify and state main objectives of the SOAR. Be as specific
as practical with regard to time frame, research strategy and/or
development of treatment strategies.
4. Establish a coordinated system of collaboration and communication
between the scientists, ideally with one scientist acting as the Chair
of the scientific working group.
5. Identify a SOAR Project Manager to monitor and coordinate the
scientific collaborative and to link the activities of the scientists
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